Status:
COMPLETED
A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction
Lead Sponsor:
Bayer
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
This purpose of the study was to evaluate the earliest time to onset of action in adults with erectile dysfunction (often called impotence). In this study vardenafil has been compared to placebo. Pati...
Eligibility Criteria
Inclusion
- Males with ED for more than 6 months according to the NIH Consensus statement(inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance)
- Heterosexual relationship
- 18 years and older
Exclusion
- Primary hypoactive sexual desire
- History of myocardial infarction, stroke or life threatening arrhythmia within the prior 6 months
- Nitrates or nitric oxide donors use
- Other exclusion criteria according to the US Product Information
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2003
Estimated Enrollment :
732 Patients enrolled
Trial Details
Trial ID
NCT00665496
Start Date
June 1 2003
End Date
November 1 2003
Last Update
December 17 2014
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85023
2
Beverly Hills, California, United States, 90212
3
San Bernardino, California, United States, 92404
4
Aurora, Colorado, United States, 80012